Xarelto (rivaroxaban), first approved in 2011, is a blood thinner that prevents the formation of blood clots. It’s used to treat a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism). The blood thinner is also used to treat atrial fibrillation (abnormal heartbeat), or …
According to research done by the CDC, many of the risk factors include cancer, immobility, pregnancy, obesity, and a history of clotting disorders. Older age (60 and older), is a significant risk factor as well.
Having a stroke can kill almost 130,000 Americans each year, so it is important that blood thinners are readily available for those who need treatment. More than 2 million Americans have an abnormal heart rhythm known as atrial fibrillation, which is an irregular heart beat that increase the risk of stroke and heart disease. For …
It is without question that blood thinners come with coherent risks. But for years, it has been said that the benefits of the medications outweigh the risks involved. However, the blood thinner industry is evolving, and now, some are concerned about a new class of blood thinners that include Pradaxa. According to Reuters, a number …
Another blood thinner is vying for a top spot to compete against the anticoagulant Warfarin, according to latest news reports. And, the US Food & Drug Administration’s Clinical Reviewer has given her initial approval, leading to a firestorm debate as to whether or not the drug is safe and should be indicated to prevent heart …
Merck & Co. is proposing another new generation blood thinner, similar to Pradaxa, which appears to also pose an increased risk of serious and potentially life-threatening bleeding events. According to results of a clinical trial presented at a meeting of the American College of Cardiology in Chicago, the proposed blood thinner Vorapaxar does appear to …